Company: PGEN
Filing Date: 2025-05-06
Form Type: PRE 14A
Source: 0001140361-25-017535
Chunk: 82

Company: PRECIGEN, INC.
Filing Date: 2025-05-06
Form: PRE 14A
Chunk 82
---
; and |

| • | transactions with a related person involving services as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture or similar services. |

In addition, the Audit Committee will review the policy at least annually and recommend amendments to the policy to the Board from time to time. The policy provides that all related person transactions will be disclosed to the Audit Committee, and all material related person transactions will be disclosed to the Board. Additionally, all related person transactions requiring public disclosure will be properly disclosed, as applicable, on our various public filings. The Audit Committee will review all relevant information available to it about the related person transaction. The policy provides that the Audit Committee may approve or ratify the related person transaction only if the Audit Committee determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. The policy provides that the Audit Committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related person in connection with approval of the related person transaction.

63

TABLE OF CONTENTS

EQUITY COMPENSATION PLAN INFORMATION The following table sets forth certain information as of December 31, 2024 with respect to securities that may be issued pursuant to outstanding awards granted under the 2013 Plan, the 2019 Plan and the 2023 Plan and authorized for issuance under the 2019 Plan and 2023 Plan. No new awards may be granted under the 2013 Plan. Each of these equity compensation plans was adopted with the approval of our shareholders.

| Plan Category                                          |     | Number of      
 Securities to  
 be Issued upon 
 Exercise of    
 Outstanding    
 Options,       
 Warrants       
 and Rights     
 (a)            |     |   Weighted- 
     Average 
    Exercise 
    Price of 
 Outstanding 
    Options, 
    Warrants 
  and Rights 
         (b) |     | Number of    
 Securities   
 Remaining    
 Available    
 for Future   
 Issuance     
 Under Equity 
 Compensation 
 Plans        
 (Excluding   
 Securities   
 Reflected in 
 column (a))  
 (c)          |
| Equity compensation plans approved by shareholders     |     | 29,928,791(1)  |     |       $7.05 |     | 9,491,435(2) |
| Equity compensation plans not approved by shareholders |     | —              |     |           — |     | —            |
| Total                                                  |     |